Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 11/20 | 0.41 |
| ▸ | CTSK | P43235 | 10/20 | 0.41 |
| ▸ | CTSB | P07858 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29168032 | 0.89 | CTSL (0.63) | JAK3BTKCTSLACECTSS | |
| SCHEMBL30714052 | 0.89 | CTSL (0.63) | JAK3BTKCTSLACECTSS | |
| SCHEMBL30133708 | 0.89 | CTSL (0.63) | JAK3BTKCTSLACECTSS | |
| SCHEMBL268923 | 0.88 | JAK3 (0.51) | JAK3BTKCTSLACECTSS | |
| SCHEMBL6345086 | 0.88 | JAK3 (0.51) | JAK3BTKCTSLACECTSS | |
| SCHEMBL22897236 | 0.88 | JAK3 (0.50) | JAK3BTKCTSLACECTSS | |
| SCHEMBL476153 | 0.86 | JAK3 (0.48) | JAK3BTKCTSLACECTSS | |
| SCHEMBL476152 | 0.86 | JAK3 (0.48) | JAK3BTKCTSLACECTSS | |
| SCHEMBL16095104 | 0.84 | KLK5 (0.54) | CTSLACECTSSCTSKCTSB | |
| SCHEMBL16095106 | 0.84 | KLK5 (0.54) | CTSLACECTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | JAK3 4766/4885BTK 4238/4885CTSL 234/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | JAK3 4609/4885BTK 3399/4885CTSL 242/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | JAK3 4766/4885BTK 4238/4885CTSL 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.